Study Objective

To evaluate the efficacy, safety and tolerability of fixed dose combination of Telmisartan (40mg) and Rosuvastatin (10mg) in the treatment of hypertension with dyslipidemia in Indian population.

Study Design

Single arm, multi-centric, non comparative, observational study.

Inclusion criteria

  • The participant diagnosed with grade 1 or grade 2 essential hypertension.
  • Sitting systolic blood pressure of ~ 130 mmHg and < 180 mmHg or sitting diastolic blood pressure of ~ 80 mmHg and < 110 mmHg at the start of the treatment period.
  • LDL- C between 130 mg/dL and 250 mg/dL.
  • Written informed consent to participate in the trial.
  • No change in diet/exercise therapy during the 3 months before the informed consent In a subject who has been on diet/ exercise therapy and instructed to improve life style. (e.g., diet and exercise)
  • Age ≥ 18 years at the time of consent.

Exclusion criteria

  • Patients with hypertension ( ie sitting systolic blood pressure 180mmHg or sitting diastolic blood pressure ≥110 mmHg), secondary hypertension, or malignant hypertension.
  • Patients with ≥ 70% luminal stenosis or requiring percutaneous coronary intervention (PCI).
  • Severely calcified coronary artery.
  • Patients who have a history of previous PCI or coronary artery bypass grafting surgery.
  • History of hypersensitivity to Telmisartan or Rosuvastatin.
  • Currently participating in any other clinical study.
  • Pregnant women, or breast feeding women.